The Challenges of Overusing Alpacas in Nanobody Research

Introduction

Alpacas have been a cornerstone of the nanobody industry, but are we overusing them? A recent Chinese report (source) reveals alarming insights into the repeated immunization and unclear histories of these animals. Here’s what’s reported:

Key takeaways in the news

Uncertainty in Antibody Discovery

• Many alpacas have been repeatedly immunized across multiple companies, often without accurate immunization records.
• This creates inefficiencies and reduces certainty in antibody discovery efforts.

Antibody Sequence Duplication

• Repeated immunization results in overlapping antibody sequences across projects.
• This threatens the uniqueness of drug candidates and risks intellectual property disputes, potentially costing companies significant time and money.

Quality Impact

• Over-immunized alpacas carry high levels of pre-existing antibodies, limiting the proportion of new, target-specific antibodies.
• Structural diversity suffers due to FR gene convergence, reducing screening efficiency.

Future Actions

These findings underline the urgent need for alternative, sustainable sources to maintain efficiency and avoid setbacks in drug development.

Explore the full report here: https://www.ktsm-life.com/news2/info.aspx?itemid=793